Iradimed (IRMD) director receives 1,026 RSUs under 2023 equity plan grant

Rhea-AI Filing Summary

Iradimed Corporation director Hilda Scharen-Guivel reported receiving 1,026 restricted stock units on December 11, 2025 under the company’s 2023 Equity Incentive Plan. The units were granted at a price of $0 and each restricted stock unit converts into one share of common stock.

The restricted stock units vest in two equal annual installments beginning on December 11, 2026, spreading the award over two years. After this grant, she beneficially owns 1,932 derivative securities, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scharen-Guivel Hilda Frederique

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/11/2025		A		1,026		(2)	(2)	Common Stock	1,026	$0	1,932	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

	/s/ Hilda Scharen-Guivel	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iradimed (IRMD) disclose in this Form 4?

A director of Iradimed reported receiving 1,026 restricted stock units on December 11, 2025 at a grant price of $0 under the 2023 Equity Incentive Plan.

Who is the reporting person in the Iradimed (IRMD) Form 4 filing?

The reporting person is Hilda Scharen-Guivel, who is identified as a director of Iradimed Corporation.

How do the new restricted stock units for IRMD’s director vest?

The 1,026 restricted stock units vest in two equal installments, with vesting beginning on December 11, 2026.

What is the conversion rate of the Iradimed (IRMD) restricted stock units?

Each restricted stock unit converts into one share of Iradimed common stock on a one-for-one basis when it vests.

How many derivative securities does the Iradimed director own after this grant?

Following the reported grant, the director beneficially owns 1,932 derivative securities (restricted stock units), held directly.

Under which plan were the Iradimed (IRMD) restricted stock units granted?

The restricted stock units were granted under Iradimed Corporation’s 2023 Equity Incentive Plan.